Pluristem Therapeutics

One under-$10 stock in the biotechnology and drugs complex that's trading within range of triggering a major breakout trade is Pluristem Therapeutics ( PSTI), which engages in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. This stock is off to a hot in 2012, with shares up over 30% so far.

Just this morning, Pluristem received an invitation from the U.S. National Institutes of Health to submit its placenta-based stem cells to the agency for evaluation in treating acute radiation syndrome. Maxim Group also initiated coverage on the stock on Wednesday with a buy rating and an $8 price target.

If you take a look at the chart for Pluristem Therapeutics, you'll notice that this stock recently broke out above some near-term overhead resistance at $2.60 to $2.65 a share with monster volume. As the stock broke out, volume clocked in at 1.9 and 4.4 million shares, which is well above its three-month average volume of 347,989 shares. Following that breakout, this stock soared and touched its recent high of $3.85 in just two trading sessions. Since tagging that high, this stock has pulled back to around $3 a share, and it's now setting up to potentially breakout again and rip higher.

>>4 Biotech Stocks Under $10 With Relative Strength

Traders should now look for long-biased trades in PSTI if it can manage to trigger a breakout trade above some near-term overhead resistance at $3.70 to $3.85 a share with high volume. Look for a sustained move or close above $3.85 a share with volume that registers near or above its three-month average action of 347,989 shares. If that breakout triggers soon, then PSTI will have an excellent chance of re-testing and possibly taking out its 2011 high of $4.38 a share. In fact, if we get a high-volume breakout, then I believe that PSTI is heading towards $5 to $6 a share after it clears $3.85 to $4.38 a share with volume.

If you're in the bull camp on PSTI, then I would look to buy this stock off any weakness, and simply use a stop around $3.20 to $3 a share. I would prefer to get long this name off strength once it clears $3.70 to $3.85 with volume, and then simply use a stop a few percentage points below $3.50 a share. Those lower stops I suggested for buying off weakness should only be used if you get into this name on a significant pullback.

If you liked this article you might like

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis

Stocks Mixed Again as Dow Declines but Nasdaq Remains on Track for Record Close

Stocks Turn Positive, Nasdaq Trades Above Record Closing High

Stock Futures Little Changed as Oil Prices Level Off